Cerecor, Inc., a Baltimore, MD-based biopharmaceutical company developing neuroscience drugs, closed a $6.8m Series A-1 financing.
The company intends to use the funds to provide working capital to complete the acquisition and technology transfer of CERC-301, a selective NR2B antagonist candidate for the treatment of depression, and the COMT platform in-licensed from Merck.
Led by Blake M. Paterson, M.D., Co-founder & CEO of Cerecor focuses on the development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human nervous system. The company is developing drugs where human proof-of-concept has been established for the target, the molecule, or both in conditions for which established biomarkers are available to facilitate development.
It has raised $30m since inception in 2011.